Vir Biotechnology, Inc.

NasdaqGS VIR

Vir Biotechnology, Inc. Cash and Short-Term Investments for the quarter ending September 30, 2024: USD 998.55 M

Vir Biotechnology, Inc. Cash and Short-Term Investments is USD 998.55 M for the quarter ending September 30, 2024, a -41.14% change year over year. Cash and short-term investments are the sum of cash and short-term investments, representing the company's liquid assets.

Vir Biotechnology, Inc. Cash and Short-Term Investments for the quarter ending September 30, 2023 was USD 1.70 B, a -27.70% change year over year.
Vir Biotechnology, Inc. Cash and Short-Term Investments for the quarter ending September 30, 2022 was USD 2.35 B, a 149.77% change year over year.
Vir Biotechnology, Inc. Cash and Short-Term Investments for the quarter ending September 30, 2021 was USD 939.45 M, a 13.65% change year over year.
Vir Biotechnology, Inc. Cash and Short-Term Investments for the quarter ending September 30, 2020 was USD 826.60 M, a 158.14% change year over year.

Key data

Date	Cash and Short-Term Investments	Receivables	Inventory	Goodwill

NasdaqGS: VIR

Vir Biotechnology, Inc.

CEO	Dr. Marianne De Backer M.B.A., M.Sc., Ph.D.
IPO Date	Oct. 11, 2019
Location	United States
Headquarters	499 Illinois Street
Employees	587
Sector	Healthcare
Industries Biotechnology Clinical Trials Pharmaceuticals Vaccines

Description

Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

Key trends

Past 5 years